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Abstract:  Inhalation of vanadium pentoxide clearly increases the incidence of alveolar/bronchiolar neoplasms in male 
and female B6C3F1 mice at all concentrations tested (1, 2 or 4 mg/m3), whereas responses in F344/N rats was, at most, 
ambiguous. While vanadium pentoxide is mutagenic in vitro and possibly in vivo in mice, this does not explain the 
species or site specificity of the neoplastic response. A nose-only inhalation study was conducted in female B6C3F1 
mice (0, 0.25, 1 and 4 mg/m3, 6 h/day for 16 days) to explore histopathological, biochemical (α-tocopherol, glutathione 
and F2-isoprostane) and genetic (comet assays and 9 specific DNA-oxo-adducts) changes in the lungs. No treatment 
related histopathology was observed at 0.25 mg/m3. At 1 and 4 mg/m3, exposure-dependent increases were observed in 
lung weight, alveolar histiocytosis, sub-acute alveolitis and/or granulocytic infiltration and a generally time-dependent 
increased cell proliferation rate of histiocytes. Glutathione was slightly increased, whereas there were no consistent 
changes in α-tocopherol or 8-isoprostane F2α. There was no evidence for DNA strand breakage in lung or BAL cells, 
but there was an increase in 8-oxodGuo DNA lesions that could have been due to vanadium pentoxide induction of the 
lesions or inhibition of repair of spontaneous lesions. Thus, earlier reports of histopathological changes in the lungs after 
inhalation of vanadium pentoxide were confirmed, but no evidence has yet emerged for a genotoxic mode of action. 
Evidence is weak for oxidative stress playing any role in lung carcinogenesis at the lowest effective concentrations of 
vanadium pentoxide. (DOI: 10.1293/tox.24.149; J Toxicol Pathol 2011; 24: 149–162)
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Introduction
Although relatively common in the Earth’s crust, vana-
dium is minable in very few regions. Its major commercial 
sources are the titanoferrous magnetites of South Africa, 
China and the former USSR. It is also found in some fossil 
fuels and is recoverable from oil, shale and coal residues1. 
It was “rediscovered” in 1830 in some iron ore in Sweden 
by Sefström, who named the element after Vanadis, the 
Scandinavian goddess of beauty, because of the intensity 
and variety of colours displayed by many of its compounds. 
Consequently, in addition to its use in the manufacture of 
certain alloys its compounds find use as pigments. Vana-
dium pentoxide specifically is used in the manufacture of 
ferrovanadium and as a catalyst in sulphuric acid manufac-
ture, where it is used in the oxidation of SO2 to SO3. When 
used to produce steel its value is in forming V4C3 with any 
carbon that is present, thereby producing a fine-grained al-
loy with increased wear resistance and strength at higher 
temperatures, properties that are valued in the manufacture 
of (jet engine) turbine blades, high-speed tools and springs. 
When alloyed with titanium and aluminium it has a num-
ber of applications, e.g., its specification Ti-6%Al-4%V is 
used in many aerospace, industrial and medical applications 
(surgical implants). Vanadium compounds are present in 
various animal and plant species, sometimes at significant 
concentrations. In ascidians (sea squirts) vanadium serves 
a physiological function as a blood pigment in vanadocytes, 
or extracellularly in plasma as haemovanadin. The concen-
trations in certain of these organisms may be surprisingly 
high (e.g., 1900 mg/kg bw in Phallusia mamillata), indicat-
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ing a high potential for concentrating the element from the 
surrounding sea water2,3. In the general human population, 
food is the major source of vanadium, the higher concentra-
tions being found in shellfish, mushrooms, parsley, dill and 
black pepper4,5. Vanadium compounds, especially insoluble 
and poorly soluble vanadium oxides, are hardly absorbed 
from the intestinal tract6, whereas they are easily absorbed 
from the lung7; occupational exposure by inhalation of the 
oxides is probably the source of more concern regarding 
possible human effects of the element. Unlike some other 
oxides of vanadium, the pentoxide is slightly soluble in wa-
ter (0.1–0.8 g/100 cm3)8,9.
Many aspects of vanadium pentoxide occurrence, use 
and toxicology have been addressed in the IARC (2006) 
monograph in which its carcinogenicity was evaluated10; 
a more truncated review was presented as part of the U.S. 
NTP technical report of the inhalation carcinogenicity stud-
ies in rats and mice11,12; and a look to the future has been 
presented in a review of toxicological concerns regarding 
vanadium pentoxide13. Conclusions reached by NTP regard-
ing the carcinogenicity of vanadium pentoxide were: “…
there was some evidence of carcinogenic activity of vana-
dium pentoxide in male F344/N rats and equivocal evidence 
of carcinogenic activity of vanadium pentoxide in female 
F344/N rats based on the occurrence of alveolar/bronchiolar 
neoplasms. There was clear evidence of carcinogenic ac-
tivity of vanadium pentoxide in male and female B6C3F1 
mice based on increased incidences of alveolar/bronchio-
lar neoplasms. Exposure to vanadium pentoxide caused a 
spectrum of non-neoplastic lesions in the respiratory tract 
(nose, larynx, and lung) including alveolar and bronchiolar 
epithelial hyperplasia, inflammation, fibrosis, and alveolar 
histiocytosis of the lung in male and female rats and mice 
and an unusual squamous metaplasia of the lung in male 
and female rats. Hyperplasia of the bronchial lymph node 
occurred in female mice”11.
The NTP carcinogenic assessment was largely con-
firmed by the IARC (2006) evaluation: “In both male and 
female mice, the incidences of alveolar/bronchiolar neo-
plasms  were significantly increased, and there were also 
increases in male rats. It was uncertain as to whether a mar-
ginal increase in alveolar/bronchiolar neoplasms in female 
rats was related to exposure to vanadium pentoxide”10. The 
results of the study, however, would not readily support a 
conclusion that there was any evidence for carcinogenicity 
in female rats (and even the results from male rats are ques-
tionable), if it was not for the clear data from mice (see Fig. 
1). Some limitations of the NTP study have been discussed 
by Duffus (2007) who also speculated on the role of nascent 
ultrafine and nanoparticles that might have been produced 
during milling as sources of reactive oxygen species14.
The pattern of carcinogenic responses in the lungs of 
mice and rats exposed by inhalation do not readily suggest 
a genotoxic mode of action and the published genetic tox-
icity and mutagenicity experiments with vanadium pent-
oxide have provided mixed responses in vitro and in vivo 
(reviewed in Assem and Levy, 2009)13. Consequently, the 
objective of the current experiments was to generate data 
that might suggest a mode of action for the clear carcino-
genic response in mice. Since the exposure period used was 
short (16 days), it was recognised from the beginning that 
there are severely limited possibilities for identifying key 
events in the process. Nevertheless, should genotoxicity 
be a major factor in the process, this ought to be definable 
within this time frame. Female B6C3F1 mice were selected 
for the study since this was the strain used by NTP in their 
whole-body exposure study and the carcinogenic response 
over the control group was greater in females than in males. 
Observations and measurements made following nose-only 
exposure to a vanadium pentoxide aerosol 6h/day for 16 
days included concentrations of V in lungs and blood, lung 
weight, histopathology of the airways, cell proliferation in 
lungs, concentrations in lungs of α-tocopherol, glutathione 
(reduced and total), 8-isoprostane F2α, as a representative of 
the isoprostanes, and 9 specific DNA-oxy-adducts and DNA 
damage (comet assays) in lung and bronchiolar-alveolar la-
vage (BAL) fluid cells. It was also planned to conduct a mi-
cronucleus assay on lung cells, but concerted and prolonged 
attempts to validate such an assay on cells from mouse lung 
were unsuccessful, so this part of the study design was 
eventually abandoned. While these efforts were in progress, 
a technique for conducting micronucleus studies on mouse 
lung cells was successfully devised and used to follow the 
effect of exposure to ethylene oxide15.
Materials and Methods
Chemicals
The primary test material, vanadium pentoxide, a 
yellow-orange solid (batch no. H060391, purity 99.8% and 
containing  0.13%  vanadium  tetraoxide),  was  supplied  by 
Stratcor Technology Center, Hot Springs, Arkanas, USA. 
Methylmethanesulphonate (stated purity 99%), the positive 
control material used in the genetic toxicity assays, was ob-
tained from Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany.
Mice and their exposure
This study was performed in an AAALAC-accredited 
laboratory in accordance with the Swiss Animal Protection 
Law under licence no. 45, “Subacute inhalation toxicity test-
ing in rats and mice with an industrial chemical.”
Female B6C3F1/Hsd mice were obtained from Harlan 
Laboratories Ltd., Dublin, Virginia, USA. The mice were 
7–8 weeks of age at delivery and their body weights ranged 
from 16.9 g to 23.2 g at acclimatisation. 192 mice were al-
located to 4 groups of 48 mice each. One additional group 
of six mice (group 5) was used as the positive control in a 
comet assay. The mice of each of the groups 1–4 were sub-
divided into eight sub-groups of six mice each to evaluate 
the range of toxicity on specific end-points in the lungs and 
to obtain data on the concentration of vanadium in blood 
and lungs. The mice of groups 1–4 were exposed to vana-
dium pentoxide for 6h/day for either 7 or 16 days at target Schuler, Chevalier, Merker et al. 151
aerosol concentrations of 0, 0.25, 1 or 4 mg/m3. During ex-
posure, the mice were confined separately in restraint tubes 
positioned radially around a flow-past, nose-only exposure 
chamber (as described by Cannon et al., 198316). The flow of 
air at each tube was 0.5 L/min, which is more than twice the 
respiratory minute volume of a mouse, and therefore suf-
ficient to minimise re-breathing of the aerosol.
Vanadium pentoxide dust aerosol was generated using 
a rotating brush aerosol generator connected to a micron-
izing jet mill. The highest exposure concentration aerosol 
generated was then electrostatically discharged into the ex-
posure chamber through a 63Ni charge neutraliser. An air-
vacuum dilution system was used to achieve the lower tar-
get aerosol concentrations. Gravimetric determinations of 
the vanadium pentoxide aerosol concentrations were made 
daily using Millipore®-durapore filters, Type HVLP (pore 
size 0.45 μm) loaded in an in-line stainless steel filter sam-
pling device (Gelman Science Inc., Ann Arbor, Michigan, 
U.S.A.). The distribution of particle size in the generated 
aerosol also was determined gravimetrically on two oc-
casions during the 16-day treatment period for the 1 and 
4 mg/m3 dose groups using a cascade impactor. In order to 
obtain sufficient material from the 1 mg/m3 concentration 
atmosphere to provide a result with reasonable precision, it 
was necessary to collect the sample over 4 consecutive days; 
but even this procedure would not have allowed estimates of 
particle size from the 0.25 mg/m3 atmospheres. Following 
these gravimetric determinations for concentration and par-
ticle size, chemical analyses of the weighed filters for vana-
dium were performed using an atomic absorption spectros-
copy (AAS) method and the results reported as vanadium or 
as vanadium pentoxide after recalculation.
Fig. 1.  Percentage incidences of pulmonary adenomas or carcinoma, and selected non-neoplastic pathology from the US NTP two-
year inhalation studies in B6C3F1 mice (A, B) and F344/N rats (C, D) for vanadium pentoxide (NTP, 2002; Resset al., 2003).Mode of Action of Vanadium Pentoxide 152
After 7 or 16 days exposure, mice were anaesthetized 
with 46% Ketamin (Ketavet 100, Pharmacia GmbH, 76139 
Karlsruhe,  Germany),  23%  Xylazin  (Rompun  2%,  Bayer 
HealthCare, 51368 Leverkusen, Germany) and 31% Mid-
azolan (Dormicum, Hoffmann LaRoche, 79639 Grenzach-
Wyhlen, Germany) (approx. 2 mL/kg body weight). In mice 
allocated for histopathology, the lungs were instilled via the 
trachea  with  neutral  buffered  4%  formaldehyde  solution. 
For biochemical and comet assay investigations the lungs 
were perfused through the right ventricle with saline, the 
lung lobes excised and, except for samples intended for the 
comet assay, they were shock-frozen in liquid nitrogen and 
shipped on dry ice to the appropriate analytical laboratory 
where they were stored at -80 °C pending analysis. For the 
comet assay, the freezing step was omitted and the lungs 
were lavaged with 20 mL mincing buffer (20 mM EDTA, 
10% DMSO in HBSS pH 7.4–7.6) for collection of bronchio-
lar alveolar lavage (BAL) cells. Perfusion of the lungs was 
continued, then they were minced in 1 mL mincing buffer 
using fine scissors to obtain a suspension of single cells.
Observations and analyses
Vanadium concentrations were measured in blood and 
lung samples from exsanguinated mice by AAS.
In addition to standard histopathology of the lungs fol-
lowing staining with haematoxylin-eosin, lung tissue sec-
tions from two of the mouse allocations (one each after 7 
and 16 days exposure) were stained for two endogenous 
proliferation markers: proliferating cell nuclear antigen 
(PCNA), that is expressed in the nuclei of cells during DNA 
synthesis and repair when it is clamped to DNA and assists 
in holding DNA polymerase δ in position, and Ki-67, which 
is a strictly nuclear protein during interphase, but relocates 
to the surface of chromosomes, where it is detectable dur-
ing all phases of mitosis. Proliferation markers PCNA and 
Ki-67 were quantified by counting all marker-positive cells 
in 5 × 1 cm2 microscope view fields/mouse at × 400 mag-
nification. The grading system applied for the proliferation 
rate assessment was as follows: 1–15 positive cells = grade 1 
minimal; 16–30 positive cells = grade 2 slight; 31–45 posi-
tive cells = grade 3 moderate; 46–60 positive cells = grade 4 
marked; >60 positive cells = grade 5 severe.
Glutathione (reduced and total) and α-tocopherol con-
centrations were measured separately in the right and left 
lung lobes, respectively, of one set of 4 groups and 8-iso-
prostane F2α was measured in another.
Reduced (GSH) and oxidised (GSSG) glutathione: Fro-
zen lung samples were homogenized in 10 volumes ice-cold 
50  mM MES ([2-(N-morpholino) ethanesulphonic acid]) 
buffer, pH 6–7, containing 1 mM EDTA. Proteins were pre-
cipitated by the addition of an equal volume of 10% meta-
phosphoric acid and centrifugation at 2000 × g for 10 min. 
The supernatant fluid was diluted 20- to 100-fold with MES 
buffer and total glutathione (GSH plus GSSG) concentration 
in lung homogenates determined spectrophotometrically at 
405 nm following reduction with glutathione reductase in 
the presence of NADPH and derivatisation with 5,5′-dithio-
bis-(2-nitrobenzoic acid) as described in the glutathione as-
say kit (Cayman Chemical Co., USA). Oxidized glutathione 
(GSSG) was quantified similarly following inactivation of 
GSH with 2-vinylpyridine at 2- to 10-fold dilutions with 
MES buffer17. For a determination of the recovery efficiency 
control lung samples were spiked with glutathione at con-
centrations of 1 and 250 μmol/g lung. Mean recovery ef-
ficiencies of 82.3 ± 15.3% (n = 3) and 76.1 ± 7.9% (n = 3), 
respectively, were obtained.
 α-Tocopherol: Frozen lung samples were homogenized 
with  10  volumes  0.9%  NaCl.  Proteins  were  precipitated 
from 250 µL of the homogenate with an equal volume of 
ethanol and α-tocopherol was extracted with 1 mL hexane. 
Following lyophilisation of 0.5 mL of the hexane extract, the 
residue was reconstituted in 100 µL acetonitrile/methanol 
(85:15). An aliquot of 50 µL was analysed for α-tocopherol 
by HPLC with fluorescence detection (excitation at 295 nm, 
emission at 330 nm) on a Nucleosil 5 μm C18 column (125 × 
4.6 mm) eluted with acetonitrile/methanol (85:15) at a flow 
of 1.5 mL/min18. For a determination of the recovery effi-
ciency, control lung samples were spiked with α-tocopherol 
at a concentration of 57.3 µg/g lung. The mean recovery ef-
ficiency was 79.5 ± 7.6% (n = 2).
  8-Isoprostane  F2α:  Frozen  lung  samples  were  ho-
mogenised in 3 volumes 0.9% (w/v) NaCl. [3H]Prostaglan-
din F2α was added as internal standard and isoprostanes 
were extracted with 2 volumes ethanol from the homog-
enate. Following centrifugation for 10 min at 1500 × g the 
supernatant fluid was hydrolysed with an equal volume 15% 
(w/v) KOH for 1 h at 40 °C to release esterified isoprostanes. 
The hydrolysate was diluted with 2 volumes water, acidified 
with 2 M HCl to pH 2.0–3.5 and loaded on an Oasis HLB 
(30 mg) SPE column (Waters, USA) equilibrated with 1 mL 
methanol and 1 mL 0.02 M HCl. The column was washed 
subsequently with 2 mL 0.02 M HCl and with 2 mL 40% 
methanol in 0.02 M HCl. The column was dried with air and 
rinsed with 2 mL heptane. Isoprostanes were eluted from 
the column with 2 mL ethyl acetate. The final elute from 
the Oasis column was diluted with 2 mL heptane, loaded on 
a Sep-Pak Vac RC Silica (100 mg) column (Waters, USA) 
equilibrated with 1 mL methanol and 1 mL ethyl acetate/
heptane (1:1 by volume), and eluted with 2 mL ethyl acetate/
methanol (1:1 by volume). The eluate was dried in a Speed-
Vac concentrator and reconstituted in 1 mL EIA (enzyme-
immunoassay)-buffer. The recovery of the extraction was 
determined by scintillation counting of 100 µL of the recon-
stituted extract. Quantitative measurement of 8-isoprostane 
F2α was made using a commercially available ELISA (Cay-
man Chemical Co., USA) using different dilutions of the ex-
tract19. For a determination of the recovery efficiency con-
trol lung samples were spiked with 8-isoprostane F2α at a 
concentration of 5 ng/g lung. The mean recovery efficiency 
was 98.8 ± 34.7% (n = 4).
Comet assay: The BAL cell preparation was centri-
fuged at 300 × g for 10 min and resuspended in 0.7% aga-
rose. The minced lung tissue cells were filtered through a 
40 µm mesh cell strainer, centrifuged at 5000 × g for 1 min Schuler, Chevalier, Merker et al. 153
and re-suspended in 0.7% agarose. Three slides per minced 
lung and one slide of BAL cell suspension per mouse were 
prepared by diluting 10% cell suspensions with 90% of 0.7% 
low melting point agarose solution and applying 0.1 mL per 
slide. Slides were cooled before submersion in lysis buf-
fer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% Triton 
X-100, 10% DMSO) at 2–8 °C in the dark (for at least 1 h 
and up to 7 days). This was followed by 20 min of alkaline 
treatment in electrophoresis buffer (0.3  M NaOH, 1  mM 
EDTA) at pH ≥ 13 and then electrophoresis for 30 min at 25 
V (0.72 V/cm), 300 mA. These operations were conducted at 
2–8 °C in the dark. The preparations were neutralised with 
0.4 M Tris, pH 7.5, dehydrated in 99% ethanol and finally 
air-dried before scoring. DNA was stained with ethidium 
bromide (20 µg/mL, 40 µL/slide) immediately before scor-
ing tail intensity in 100 cells per preparation (BAL cells or 
minced lung tissue cells) from each mouse using a fluores-
cence microscope with a 40 × objective linked to an image 
analysis programme (Comet Assay IV, Perspective Instru-
ments). The numbers of apoptotic and necrotic cells/500 
cells per slide also were recorded in order to indicate the 
quality of slide preparation and exclude possible cytotoxic 
effects. Because the target cell populations were unusual for 
this type of assay, a small historical database was accumu-
lated for both BAL and minced lung cells from untreated 
mice. The percentage tail intensities in this database were: 
BAL cells, mean 0.66 ± 1.26 SD, range, 0.04–6.34, n = 27; 
lung cells, mean 0.42 ± 0.60 SD, range, 0.04–3.29, n = 32. A 
positive control group of mice was dosed orally by gavage 
with methylmethanesulphonate (MMS), 200 mg/Kg body 
weight 4 h before they were killed. Data were analysed for 
statistical significance using the one-tailed Student’s t-test.
DNA oxo-lesions:
1) DNA extraction
Nuclear DNA was isolated according to a method opti-
mised for the study of oxidised nucleosides20. Thawed lung 
samples were minced with scissors and homogenised in 
1.5 mL of ice cold lysis buffer A (320 mM sucrose, 5 mM 
MgCl2, 10 mM Tris, 0.1 mM deferoxamine pH 7.5, 1% Tri-
ton-X100) using a polytron homogeniser. The nuclei were 
recovered by centrifugation at 1500 × g for 10 min at 4 °C. 
The nuclear pellets were washed with 1.5 mL of buffer A 
and after re-centrifugation (1500 × g, 10 min) they were re-
suspended in 600 µL of lysis solution B (10 mM Tris, 5 mM 
EDTA-di-Na, 0.15 mM deferoxamine, pH 8.0) and 35 µL of 
10% SDS. Then, 30 µL of RNase A (1 mg/ml) and 8 µL of 
RNase T1 (1 U/μl) were added and the resulting solutions 
were incubated at 50 °C for 15 min. Subsequently, 30 µL of 
Qiagen protease (20 mg/ml) were added and the resulting 
solutions were incubated at 37 °C for 1 h after which they 
were centrifuged at 5000 × g for 15 min at 4 °C. The su-
pernatant fractions were collected and mixed with 1.2 mL 
of sodium iodide solution (7.6 M NaI, 40 mM Tris, 20 mM 
EDTA-di-Na, 0.3 mM deferoxamine, pH 8.0) and 2 mL of 
cold (4 °C) 2-propanol. DNA precipitation was obtained by 
gently inverting the tube several times. DNA was recovered 
by centrifugation at 5000 × g for 10 min at 4 °C and washed 
with 1 mL of 40% 2-propanol. After re-centrifugation at 
5000 × g for 10 min the DNA sample was washed again us-
ing 1 mL 70% ethanol. Finally, the DNA sample was again 
recovered by centrifugation and suspended into 50 µL of 
0.1 mM deferoxamine and stored frozen at −80 °C until di-
gestion.
2) DNA digestion
To 50 µL of the DNA solution was added 2.5 µL of buf-
fer P1 10x (200 mM succinic acid, 100 mM CaCl2, pH 6.0) 
1 U of nuclease P1, 2.5 U of DNAse II and 0.025 U of phos-
phodiesterase II. The resulting solution was incubated for 
2 h at 37 °C. Thereafter, 6 µL of alkaline phosphatase buffer 
10× (500 mM Tris, 1 mM EDTA, pH 8) was added together 
with 0.015 U of phosphodiesterase I and 2 U of alkaline 
phosphatase. The samples were then incubated at 37 °C for 
2 h. After enzymatic digestion, the solution was neutralized 
by addition of 3.5 µL of 0.1 M HCl. Then, the samples were 
centrifuged for 5 min at 5000 × g and transferred in HPLC-
compatible vials prior to HPLC-MS/MS analysis. Traces of 
ethanol used for DNA precipitation were removed by put-
ting the samples in a speed vac concentrator for 10 min (not 
more to avoid drying of samples). Directly after digestion 
samples were analysed by HPLC-MS/MS for which 20 µL 
of the solution was injected on to the HPLC column. HPLC-
MS/MS measurements were performed using an Accela 
HPLC system coupled through electrospray to a Quantum 
Ultra triple quadrupole mass spectrometer. Separation was 
achieved on an octadecylsilyl silicagel Hypersyl (particle 
size: 3 μm, 150x2.0 mm I.D.) column obtained from Inter-
chim (Montluçon, France). The mobile phase consisted of an 
increasing proportion of methanol (from 0 to 15% in 35 min) 
in 2 mM ammonium formate, adjusted to pH 4.8 with for-
mic acid. The flow rate was 0.2 mL/min. Detection of the 
different DNA lesions was performed in the so-called mul-
tiple reactions monitoring (mrm) mode. Transitions used for 
detection of the different DNA lesions and the limits of their 
detection are given in Results DNA lesions. Results are ex-
pressed as the number of lesions relative to the number of 
normal nucleosides detected using an online UV detector 
at 260 nM.
Results
In vivo and post mortem observations
Measured aerosol concentrations were very close to the 
0, 0.25, 1 and 4 mg/m3 target concentrations (Table 1). The 
mass median aerodynamic diameters (MMAD) of the gen-
erated aerosols ranged between 1.22 and 1.43 μm and the 
Table 1.  Mean V2O5 Concentrations in Air during Exposure of 
Mice 6 h/day for 16 Days
Exposure group
V2O5 concentrations in air (mg/m3)
Target Actual A/T
1 0 Not measured  
2 0.25 0.246 ± 0.026 98% ± 10%
3 1.00 0.993 ± 0.122 99 ± 12%
4 4.00 4.01 ± 0.55 100% ± 14%Mode of Action of Vanadium Pentoxide 154
mean percentage of particles of < 3 µm diameter were 92 
at 1 mg/m3 and 91 at 4 mg/m3. The MMAD at 0.25 mg/m3 
was assumed to be similar to the other groups because the 
two lower target aerosol concentrations were achieved by 
air-vacuum dilution from a single aerosol that provided the 
4 mg/m3 exposure concentration and the ranges of MMADs 
at 1 and 4 mg/m3 were similar.
One mouse in the 1  mg/m3 group was found dead 
shortly after the end of exposure during the second week 
of treatment, although it was most likely not a treatment-re-
lated event since no clinical signs of toxicity were observed 
during the study. During the first week of exposure, mar-
ginal body weight losses were noted in the 1 and 4 mg/m3 
groups that were statistically significant in the higher group, 
but had resolved during the second week. Lung weights 
showed a dose-related increase in these same groups. In the 
groups killed after 7 days, there were no effects on the lung 
weights in the 1 mg/m3 group and the statistically signifi-
cant increased lung weight in the 4 mg/m3 group was less 
pronounced (Table 2). The increases in lung weights were 
not attributable to deposition of vanadium pentoxide, al-
though vanadium concentrations showed clear, dose related 
increases in both lung and blood (Table 3). It is more likely 
the lung weight increases were due to an influx of fluid and 
cells in an inflammatory response.
In the mice killed after 16 days exposure, the following 
histopathological diagnoses were made:
• ultifocal/diffuse alveolar histiocytosis that was to some 
degree dose-dependent in all 6 mice of the 1 and 4 mg/m3 
groups;
• ultifocal subacute alveolitis that was clearly dose-depen-
dent in 5 mice each of the 1 and 4 mg/m3 groups; and
• ultifocal granulocytic infiltration at similar severity in 4 
mice at 1 mg/m3 and 5 mice at 4 mg/m3.
No treatment-related pathology was noted in mice ex-
posed to 0.25 mg/m3 for 16 days. Examples of these findings 
are shown in Fig. 2.
Cell proliferation
The mean cell proliferation rate grades, as indicated 
by immunohistochemical staining for Ki-67 protein after 
7 and 16 days, were time-dependently and dose-relatedly 
increased in the 1 and 4 mg/m3 groups. There were also 
dose-related increases in immunohistochemical staining for 
PCNA in the 1 and 4 mg/m3 groups after 7 days, but only 
in the 4 mg/m3 group after 16 days, the score for the 1 mg/
m3 group at this time being similar to the controls. Thus, 
a time-related increase was observed only in the 4  mg/
m3 group when staining for PCNA (Table 4). With neither 
method was there evidence for cell proliferation following 
exposure to 0.25 mg/m3.
Glutathione
Reduced glutathione is the most abundant water-solu-
ble cellular scavenger for reactive oxygen species. Induction 
of oxidative stress might result in a depletion of GSH with 
an accompanying increase of oxidized glutathione, GSSG. 
The respective tissue concentrations, therefore, are gener-
ally considered to be measures of intracellular oxidative 
stress21.
Mean GSH concentrations in the lungs of mice ex-
posed to 0.25 mg/m3 were slightly but statistically signifi-
cantly lower (17.4%) than the control value (Table 5), where-
as there were no significant differences from the control in 
mean GSH concentrations in the lungs of the 1 and 4 mg/
m3 groups. However, there were slightly but significantly 
increased concentrations of GSSG in the lungs of mice 
from all treatment groups, although indications of a concen-
tration-related effect were weak, the percentage increases 
being 159%, 223% and 215% in the 0.25, 1 and 4 mg/m3 
groups, respectively.
As a result of the increased GSSG concentrations the 
ratio of reduced to oxidized glutathione (GSH/2 × GSSG) 
decreased slightly in all dose groups to 53%, 55% and 53% 
of the control group ratio in the 0.25, 1 and 4 mg/m3 groups, 
respectively.
Table 3. Vanadium Concentrations in Blood and Lungs after Expo-
sure of Mice 6 h/day for 16 Days to Vanadium Pentoxide.
Exposure group
Vanadium concentration
Blood [μg/L] Lung [μg/g]
0.25 mg/m3 –a 8.02 ± 0.84
1 mg/m3 51.15 ± 6.02 31.01 ± 2.22
4 mg/m3 160.13 ± 16.48 64.35 ± 7.45
aBelow lowest calibration point (13 µg/L).
Table 2.  Lung Weights of Mice from Exposure Groups 1–4 in 5 Independently Processed Sub-groups
Allocation sub-groups (n=6)
V2O5 concentrations in air (mg/m3)
0 0.25 1 4
 V concentration in blood and lungs 0.120 g 0.124 g 0.147 gc 0.186 gc
 Lung cell proliferation (day 7) 0.158 g 0.155 g 0.153 g 0.177 gb
 Lung cell proliferation and histopathology (day 16) 0.138 g 0.151 g 0.168 gc 0.199 gc
 Lung tissue glutathione and α-tocopherola 0.086 g 0.100 gc 0.107 gc 0.127 gc
0.043 g 0.047 g 0.052 gc 0.062 gc
 Lung tissue 8-isoprostane F2α 0.140 g 0.136 g 0.156 gb 0.197 gc
a Right (upper) and left (lower) lobes weighed separately. b p ≤ 0.05; c p ≤ 0.01.Schuler, Chevalier, Merker et al. 155
Fig. 2.  Photomicrographs of lungs from female B6C3F1 mice showing focal and diffuse alveolar histiocytosis after exposure to vanadium 
pentoxide 4 mg/m3 6h/day for 16 days (b–f) or air control (a). Magnifications ×160 (a, b, e) or ×250 (c, d, f). All staining was with hae-
matoxylin and eosin. a: control, b: diffuse histiocytosis in entire left and right cranial lobe, c: as b, d: histiocytosis and granulocytosis, 
e: alveolitis and histiocytosis, f: as e.Mode of Action of Vanadium Pentoxide 156
α-Tocopherol
α-Tocopherol was measured as a representative of lipid 
soluble cellular scavengers for reactive oxygen species that 
might be depleted under conditions of intracellular oxida-
tive stress21, but there were no consistent effects of treatment 
upon the mean α-tocopherol concentrations in lungs (Table 
5). While there was a small, statistically significant reduc-
tion in the 0.25 mg/m3 group there was no effect at 1 mg/
m3 and a small, statistically significant increase at 4 mg/m3.
F2-isoprostane
F2-isoprostanes are derived from polyunsaturated 
fatty acids, e.g., arachidonic acid, in cell membrane lipids 
by non-enzymic, free radical oxidation, so an increase in 
their concentration can be another indication of treatment-
related oxidising activity. 8-Isoprostane F2α was measured 
as a representative of this group. There were no significant 
changes in its concentration in the lungs of the mice exposed 
to vanadium pentoxide, the mean values being less than in 
the controls in all groups, but the variation within the data 
was relatively large (Table 5).
Comet assay
In BAL cells, there was a small, non-significant in-
crease in percentage tail intensity in the 1 mg/m3 group (p 
= 0.234), but there was no indication of an exposure con-
centration-related response (Table 6). In the lung cell prepa-
rations there were no increases in percentage tail intensity 
in any group exposed to vanadium pentoxide. The positive 
control, MMS, produced large increases in tail intensity in 
both BAL (p < 0.001) and lung (p = 0.004) cells.
DNA lesions
The quantities of some for the DNA lesions analysed 
(Fig. 3) were below the limit of detection by the methods 
used. These lesions included 8-oxodAdo, 5-OH-dCyd, 
ThdGly, 5-hmdUrd, 5-FodUrd, EdGuo and EdAdo. There-
fore, it cannot be concluded that treatment of mice with va-
nadium pentoxide was without effect on the generation of 
these lesions in lung cells, only that their natural and any 
induced occurrences were below the detection limits indi-
cated in Table 7. Levels of 8-oxodGuo and dCyd341 were 
high enough to enable their quantification by HPLC-MS/
MS in all the analysed mouse lung samples. The reported 
levels of these DNA lesions, expressed as the numbers of le-
sions per million normal nucleosides are reported in Table 8. 
In conclusion, statistically significant, concentration-related 
increases in 8-oxodGuo were observed in the 1 and 4 mg/
m3 groups in comparison with the control group, whereas 
there was no increase in the 0.25 mg/m3 group. In the case 
of dCyd341, no significant variation from the background 
level was observed in any group.
Table 4.  Cell Proliferation in Lungs of Mice Exposed to Vanadium Pentoxide for 7 or 16 Days
Indicator and sample time
V2O5 concentrations in air (mg/m3)
0 0.25 1 4
 Ki-67-positive cells after 7 days 10.1 (1) 11.4 (1) 18.1 (2) 24.7 (2)
 Ki-67-positive cells after 16 days 10.0 (1) 9.2 (1) 27.1 (2) 87.8 (5)
 PCNA-positive cells after 7 days 25.1 (2) 25.0 (2) 41.4 (3) 47.8 (4)
 PCNA-positive cells after 16 days 33.0 (3) 26.3 (2) 34.9 (3) 68.3 (5)
Figures in parentheses indicate the severity grades as described in the Materials and Methods section.
Table 5.  Concentrations of Indicators of Oxidative Stress (Glutathione, α-tocopherol, 8-isoprostane F2α) in the Lungs of Female B6C3F1 
Mice Exposed by Inhalation to Vanadium Pentoxide for 16 Days
Parameter
V2O5 concentrations in air (mg/m3)
0 0.25 1 4
 GSH µmol/g Lung ± SD 1.95 ± 0.30 1.61 ± 0.31a 2.26 ± 0.27 2.21 ± 0.28
 GSSG µmol/g Lung ± SD 0.168 ± 0.036 0.268 ± 0.073b 0.376 ± 0.161b 0.363 ± 0.103b
 Ratio GSH/2 × GSSG 5.95 ± 1.18 3.15 ± 0.79b 3.29 ± 0.85b 3.12 ± 0.75b
 α-tocopherol µg/g Lung ± SD 8.24 ± 1.60 6.72 ± 1.24a 8.37 ± 0.97 10.42 ± 0.74b
 8-isoprostane F2α ng/g Lung ± SD 39.8 ± 23.9 24.7 ± 11.1 31.5 ± 25.5 30.4 ± 7.2
a p ≤ 0.05; b p ≤ 0.01.
Table 6.  Comet Assay Mean Percentage Tail Intensities in BAL and Lung Cells of Female B6C3F1 Mice Exposed by Inhalation to Vana-
dium Pentoxide for 16 Days or 4 h after 200 mg MMS/Kg Body Weight Orally by Gavage
Cell type scored
V2O5 concentrations in air (mg/m3) MMS
0 0.25 1 4 200 mg/Kg
 BAL cells 0.97 ± 0.94 0.31 ± 0.32 2.34 ± 2.23 0.28 ± 0.12 65.10 ± 9.95
 Lung cells 0.53 ± 0.43 0.62 ± 1.00 0.21 ± 0.14 0.43 ± 0.40 48.34 ± 11.88Schuler, Chevalier, Merker et al. 157
Discussion
The original objective of the experiment described here 
was in the nature of a hypothesis-generating study investi-
gating the species difference in tumorigenic response to in-
haled vanadium pentoxide. The U.S. NTP (2002) had clearly 
shown that B6C3F1 mice were susceptible to tumours of the 
bronchi and alveoli when exposed to atmospheric concen-
trations of vanadium pentoxide of 1, 2 or 4 mg/m3 and that 
within this concentration range there was little indication 
of concentration dependence in the response11. Thus, the 
overall rates for adenomas or carcinomas of the alveoli and 
bronchi  at  these  concentrations,  respectively,  were  84%, 
86% and 86% for male mice and 64%, 70% and 64% for 
female mice11,12. Female mice were selected for study here 
because the induced response was greater than in males 
amongst which control group overall tumour rates were 44% 
whereas they were only 2% in females. The corresponding 
overall tumour rates for rats exposed to 0, 0.5, 1 or 2 mg/
m3, were 8%, 20%, 13% and 18% for males and 0%, 6%, 
2% and 2% for females. Since there is only a four-fold dif-
ference in concentrations it could have been that there was 
no real difference in received dose at the target tissue for 
each species. Also, the difference in inhalation characteris-
tics of rat versus mouse could have resulted in a far larger 
dose to the target tissue in mouse compared to rat. Being 
fully aware of these complexities, the NTP incorporated ki-
netic studies11,27 in parallel with the rat and mouse studies 
of carcinogenicity. These kinetic studies were reported to 
show that the lung burdens of vanadium appeared to reach 
steady-state with time at the lowest administered concen-
trations (0.5 mg/m3 for rats and 1 mg/m3 for mice), but at 
higher concentrations the lung burdens in both species de-
clined with time after reaching maximum values at about 6 
months for rats and 1–2 months for mice. The tabulated data 
in Dill et al. (2004) also suggest that, if the only determinant 
for lung tumours was the lung burden of vanadium (µg V/g 
lung) then one might predict the tumour incidences in fe-
male rats exposed to 1 or 2 mg/m3 to be very similar to the 
incidences in female mice exposed to the same atmospheric 
concentrations of vanadium pentoxide27. This is because the 
lung burdens at these concentrations in the two species were 
very similar throughout the exposure period, with eight 
measurements taken, beginning on day 1 and ending on day 
535. It is also noted that these lung weight-specific vana-
dium burdens were approximately three-fold higher in the 
Fig. 3.  Structures of purine and pyrimidine nucleosides specifically 
analysed by the techniques described in the Materials and 
Methods section.
Table 7.  Transitions Used for Detection of the Different DNA Lesions, Together with The Limits of Detection
Nucleoside oxidation 
product
Transition Limit of detection (lesions per  
106  nucleosides)
Reference
8-oxodGuo 284 → 168 0.05 Ravanat et al., 199822; Frelon et al., 200023;
8-oxodAdo 268 → 152 0.8 Frelon et al., 200023;
5-OH-dCyd 244 → 128 0.1 Riviere et al., 200624;
ThdGly 275 → 116 0.3 Frelon et al., 200023;
5-hmdUrd 257 → 126 0.1 Frelon et al., 200023;
5-FodUrd 255 → 212 0.2 Frelon et al., 200023;
dCyd341 342 → 226 0.02 Regulus et al., 200725;
EdGuo 292 → 176 0.02 Douki et al., 200426;
EdAdo 276 → 160 0.01 Douki et al., 200426;
Table 8.  Levels of 8-oxodGuo and dCyd341 Measured in Mouse Lung Samples Following Exposure to Vanadium Pentoxide
Nucleoside oxidation product
V2O5 concentrations in air (mg/m3)
0 0.25 1 4
 8-oxodGuo mean ± SD 0.24 ± 0.04 0.26 ± 0.07 0.43 ± 0.14a 0.49 ± 0.11b
 dCyd341 mean ± SD 0.067 ± 0.007 0.061 ± 0.028 0.075 ± 0.022 0.068 ± 0.010
Values are expressed as the numbers of lesions/106 nucleosides. a p < 0.01; b p < 0.001Mode of Action of Vanadium Pentoxide 158
highest exposure group compared with the lowest exposure 
group for both female rats and female mice; consequently 
lung burden parity cannot be invoked to explain the lack of 
exposure-related increases in tumorigenic responses, unless 
it is suggested that a plateau has been reached in pathology 
development even at the lowest vanadium pentoxide expo-
sure concentration. This also appears unlikely, however, be-
cause the non-neoplastic pathology in the same organs does 
show exposure concentration-related incidence increases 
in male and particularly in female rats and mice (see Fig. 
1). Furthermore, the profound species differences in tu-
morigenic responses in the NTP study11,12 do not have their 
counterparts in the non-neoplastic lung pathology, such as 
the incidences of hyperplasia of the alveolar epithelium or 
the bronchiolar epithelium and the incidences of histiocytic 
infiltration of the alveoli.
The NTP11 found no evidence for genetic toxicity 
from use of the in vitro Salmonella/microsomal assay (S. 
typhimurium strains TA1535, TA100, TA97, TA98 and 
TA102) and in contrast to a number of other studies, which 
were reviewed in Assem and Levy (2009)13, there was no 
evidence for micronucleus induction in an in vivo assay of 
peripheral blood cells from mice that had been exposed to 
vanadium  pentoxide  by  inhalation  at  five  concentrations 
ranging from 1 to 16 mg/m3 for three months. Now, pen-
tavalent vanadium compounds form vanadates and vana-
date derivatives in aqueous media and there are many ex-
amples in publications from the 1980’s and 1990’s that rapid 
reduction of vanadium(V) to vanadium (IV) compounds 
occurs in the presence of thiols such as reduced glutathione, 
cysteine, 2-mercaptoethanol and dithiothreitol (DTT) under 
physiological conditions28. Should these assertions be cor-
rect, it is possible that the NTP’s peripheral blood micronu-
cleus test may not reflect activity occurring at the site of first 
contact of vanadium pentoxide. Reduced glutathione forms 
weak complexes with tetravalent vanadium (VIV) and even 
weaker ones with VV, because it will undergo oxidation 
while VV is reduced29. However, it has been demonstrated 
that 2-mercaptoethanol forms complexes with both VV and 
VIV, and recent studies have found that, at pH 7, the amount 
of VV compared with the amount of VIV that is bound to the 
ligand is 106 greater at 1 mM and 500-fold greater at 1µM, 
suggesting not only a greater stability of vanadate-2-mer-
captoethanolate complex but also that vanadate can coexist 
in solution with 2-mercaptoethanol28. In addition to reduc-
tion, therefore, vanadate complexes might be stable in the 
presence of reduced glutathione. Consequently, the NTP’s 
peripheral blood micronucleus assay could be adequate for 
the assessment of genotoxic effects with relevance to lung 
carcinogenesis.  Verification  of  this  suggestion  requires 
study of vanadium speciation in mouse-derived blood. Such 
studies have been conducted in ascidians, using vanadium 
K-edge X-ray absorption spectroscopy30, but apparently not 
in mammalian blood. In the absence of such information, it 
was considered preferable to include as part of the current 
study an examination of possible genetic toxicity as well as 
other possible components of a mode of action within the 
known target tissue for carcinogenesis.
Administration of vanadium pentoxide at actual mean 
concentrations very close to the targets of 0.25, 1 or 4 mg/
m3 air for at least 16 days to mice by nose-only, flow-past 
inhalation exposure resulted mainly in pulmonary effects 
(increased lung weight, inflammatory lesions, DNA lesions 
and increased cell proliferation rate) at the two higher expo-
sure levels only, with increasing dose-dependent severity. 
Dose-related increases in lung weight that occurred in the 1 
and 4 mg/m3 groups were not the simple result of vanadium 
pentoxide deposition: the quantities deposited over 16 days 
were insufficient to account for the observed lung weight 
increases. A much more likely explanation is that the weight 
increases were due to the recruitment of inflammatory cells 
and an accumulation of fluid within the pulmonary tissues. 
Deposition of vanadium pentoxide particles in the lungs was 
considered to result in histopathological changes in the 1 
and 4 mg/m3 groups that may have been the result of incom-
plete particle clearance from the lung as well as a direct tox-
ic action on the pulmonary epithelium induced by the oxide. 
It is plausible that macrophages involved in the clearance 
process were unable to destroy the phagocytised particles, 
died and released pro-inflammatory cytokines which would 
have resulted in the attraction of yet more inflammatory 
cells and in a sustained oxidative stress. Indeed, Rondini 
et al. (2010)31 have demonstrated increases in keratinocyte-
derived chemokine(KC), monocyte chemoattractant protein 
1 (MCP-1), macrophage inflammatory protein-2 (MIP-2), 
NFκB and c-FOS binding activity as well as sustained phos-
phorylated ERK1/2 binding activity in lung homogenates 
from mice of strains susceptible to pulmonary inflammation 
that were treated with vanadium pentoxide (5 weekly aspi-
ration of 4 mg/kg body weight) after a single intraperitoneal 
injection of 3-methylcholanthrene (10 mg/kg body weight). 
This treatment regime also resulted in pulmonary tumour 
promotion with an increased tumour multiplicity that fol-
lowed the susceptibility to inflammation, i.e., A/J > BALB/
cJ while C57BL/6 J was refractory to tumour promotion and 
showed the weakest inflammatory response. Rondini et al. 
(2010) suggest that the tumorigenic activity of particulate 
vanadium pentoxide in mouse lung is a strain-specific aug-
mentation of lung carcinogenesis in susceptible individuals 
through oxidative stress mediated pathways31.
Such an explanation is in accordance with the small, 
statistically significant increase in 8-oxodGuo levels in the 
1 and 4 mg/m3 groups, although there are alternative expla-
nations for this oxo-adduct lesion change. Any increases 
in seven of the specific DNA lesions investigated would 
have been at very low frequencies below the limits of de-
tection listed (Table 7). Vanadium pentoxide might have 
been reasonably predicted to produce a broader spectrum 
of damage if, indeed, oxidation was the mechanism leading 
to the increase in 8-oxodGuo. It was once believed that the 
steady-state amount of DNA oxidation were very large in 
comparison with non-oxidative adducts32,33, although it is 
not clear how much of this apparent difference was due to 
unrecognised inadequacies in DNA processing. Oxidation Schuler, Chevalier, Merker et al. 159
lesions of DNA occur at high daily frequencies under non-
stress conditions and this lesion in particular is normally 
rapidly and efficiently repaired34,35. It has been estimated 
that in liver of homozygous ogg1−/− (i.e., oxoguanine gly-
cosylase repair enzyme deficient) mice the level of 8-oxodG 
accumulates at a rate of 12,000 modifications per diploid 
cell per week, based on measurements at 14 weeks of age 
compared with 9 weeks36. Hydroxyl radicals (HO•) is one 
of the reactive oxygen species involved in oxidative stress 
and is held responsible for the formation of both 8-oxo-7,8-
dihydro-2´-deoxyguanosine (8-oxodGuo) and, to a minor 
extent, 8-oxo-7,8-dihydro-2´-deoxyadenosine (8-oxodA-
do)37. 8-oxodGuo can also be produced by singlet oxygen 
(1O2), this being a highly specific reaction in that guanine is 
the exclusive target in DNA38,39. Experiments in which 1O2 
was the only reactive oxygen species generated have shown 
that it produces predominantly Fpg-sensitive sites that are 
detectable with the comet assay and attributable in the main 
to 8-oxodGuo, as confirmed by HPLC-MS/MS measure-
ments20,40. Endo III-sensitive sites (attributed to oxidized 
pyrimidines) were not generated, thereby demonstrating an 
absence of oxidised pyrimidine lesions39. Amongst several 
other mechanisms by which 8-oxodGuo can be produced is 
the formation of tandem lesions. Peroxyl radicals of a py-
rimidine base can react with a vicinal DNA base (i.e., where 
2 functional groups are bonded by 2 adjacent atoms) by ad-
dition of the pyrimidine peroxyl radical onto the C8 of a 
purine is capable of producing 8-oxodGuo that is involved 
in a tandem lesion on a neighbouring formylamine41,42. Al-
though this specific lesion may account for no more than 
10% of 8-oxodGuo, there may be other 8-oxodGuo contain-
ing tandem lesions produced by similar mechanisms. These 
tandem lesions generated by hydroxyl radicals are at least 
partly refractory to excision repair by DNA glycosylases43. 
In addition, one-electron oxidation of DNA would gener-
ate mostly 8-oxodGuo44 and thus Fpg sensitive sites with-
out creating a large number of direct strand breaks45, as ob-
served in potassium bromate treated cells46. Consequently, 
an alternative to lesion induction as the reason for the in-
crease in 8-oxodGuo is the inhibition of repair enzyme ac-
tivity by vanadium ions or complexes. However, the rate of 
accumulation is reported to be tissue-specific and lung is not 
one of the organs examined47 so this hypothesis remains to 
be tested although inhibitory activity of vanadium towards 
specific enzymes is well-documented29. Furthermore, va-
nadium pentoxide might have been reasonably predicted to 
produce a broader spectrum of damage if, indeed, oxidation 
was the mechanism leading to the increase in 8-oxodGuo.
The comet assay result did not support an involvement 
of genetic toxicity in a mode of carcinogenic action for va-
nadium pentoxide, although the concentrations of vanadi-
um measured in lungs of the mice after 16 days exposure 
(Table 3) suggest that, if this had been an in vitro study a 
significant response would have been possible. Vanadium in 
lung measurements found during the current study (Table 3) 
would translate into concentrations between 8 and 64 µg V/
mL culture medium, which is comfortably within the effec-
tive vanadium pentoxide concentration range for significant 
comet assay responses in vitro48–50. This assay is dependent 
on the formation of DNA strand breaks. If, as has been sug-
gested51, vanadium pentoxide interferes with tubulin poly-
merisation and thereby causes aneuploidy then this would 
not have been detected with the comet assay, but could have 
been in a micronucleus test. Such assays have been con-
ducted, but unfortunately not in the target tissues for car-
cinogenesis. The soluble VV salts sodium orthovanadate 
(Na3VO4) and ammonium metavanadate (NH4VO3) as well 
as the VIV compound, vanadyl sulphate (VOSO4), increased 
the frequencies of cells with micronuclei, aneuploidy and 
(but only for vanadyl sulphate) structural chromosomal 
aberrations in bone marrow cells of mice treated orally by 
gavage52, although the micronucleus test positive reported 
for sodium orthovanadate in this study was not confirmed 
either in a more recent study after i.p. injection of 25 mg/
Kg body weight53 or in a drinking water study of vanadyl 
sulphate at exposures up to 1000 mg/L for 5 weeks54. In this 
last study, the concentration of vanadium measured in the 
target tissue (femur) was 13.03 µg V/g. No strictly compara-
ble measurements of vanadium in the target organ are avail-
able following 16 weeks exposure to vanadium pentoxide 
(16 mg/m3 6h/day, 5 days/week) by inhalation in the study 
of micronucleus induction conducted by NTP11. The closest 
to an appropriate vanadium measurement for comparison in 
female mice comes from the 2 year segment of that study in 
which the highest exposure was to 4 mg/m3 and the highest 
blood concentration of vanadium was only 1.1 µg/g blood at 
26 days11. Thus, the absence of an effect can be ascribed to 
the low concentration of vanadium VV at the target cells or 
to selection of resistant cell populations in the marrow dur-
ing the three months inhalation exposure in the NTP study, 
but not because of possible valence changes VV to VIV upon 
inhalation.
Other indicators of oxidation status measured in the 
study included α-tocopherol, but alterations in the levels of 
this antioxidant (a decrease at 0.25 mg/m3 and an increase 
at 4 mg/m3) were considered to be of no biological signifi-
cance. GSSG, as the oxidation product of GSH, was slightly 
increased with a weak dose-relationship, possibly as a result 
of either scavenging reactive oxygen by GSH or because of 
its interaction with vanadium pentoxide. While an accom-
panying decrease in GSH might then be expected, GSH is 
much less affected due to its 10-fold constitutive excess (see 
the control groups in Table 5). In addition, the de novo syn-
theses of GSH and glutathione reductase are known to be 
induced very quickly by oxidative stress, thereby compen-
sating for any depletion of GSH. Nevertheless, the increase 
in GSSG was marginal in this experiment. This weak re-
sponse finds support in the absence of a significant change 
in isoprostane levels, indicating that the natural defence 
mechanisms of the lung against oxidative stress were suf-
ficient to protect the tissues in all groups against a weak oxi-
dative stress that might be induced by vanadium pentoxide. 
It is noted, however, that a different pattern of responses 
has been observed in the livers of streptozotocin-induced Mode of Action of Vanadium Pentoxide 160
diabetic rats treated with vanadate (as Na3VO4), where re-
duced glutathione levels decreased while GSSG levels and 
glutathione reductase activity remained unchanged55.
Inflammatory  lesions  in  the  lungs  consisting  of  al-
veolar histiocytosis, alveolitis and granulocytic infiltration 
were noted in the 1 and 4 mg/m3 groups and confirm the 
observations made in the NTP study over a similar expo-
sure period at concentrations down to 2 mg/m3,11,12. A cor-
responding increase in the proliferation rate of histiocytes 
was demonstrated in mice of the current study exposed to 
1 mg/m3 for either 7 or 16 days that confirmed the increases 
in bromodeoxyuridine-labelled lung nuclei reported in the 
terminal bronchi after exposure of female mice to 2 mg/m3 
and female rats to 1 mg/m3 for either 6 or 13 days in the 
NTP (2002) study11. These pathological findings were con-
cordant with the increased lung weights and were probably 
related to an incomplete lung clearance of particulates. This 
response may also have contributed to the marginal body 
weight loss during the first week of this 16-day study.
In  conclusion,  several  of  the  pathological  findings 
made in the short-term whole-body exposure studies con-
ducted by the NTP (2002)11 have been confirmed and the 
absence of evidence from that study for a genotoxic mode 
of (carcinogenic) action extended to the target tissues, at 
least as observable with the comet assay. It is not yet clear 
whether the increase in 8-oxodGuo DNA lesions was due 
to induction by vanadium pentoxide or inhibition of repair 
of spontaneous lesions and evidence is weak for oxidative 
stress playing any role in lung carcinogenesis at the lowest 
effective concentrations of vanadium pentoxide.
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